How Does Terminal Sterilization Shift the Complex Equilibrium in Parenteral HPBCD Solutions?

Parenteral solubilization with hydroxypropyl betadex (HPBCD) is selected when the active pharmaceutical ingredient exhibits aqueous solubility below 5 µg/mL and log P above 3.5. Injection-grade HPBCD differs from oral-grade material by tighter bioburden, bacterial endotoxin, sub-visible particle, and elemental impurity controls, with manufacture governed by 21 CFR Part 211 and EU GMP Annex 1. The preparation train uses a jacketed 316L stainless steel vessel with radial impeller mixing at 100–300 rpm; Water for Injection is nitrogen-sparged to maintain dissolved oxygen below 0.1 mg/L before HPBCD is dissolved. Final parenteral concentration is typically 100–400 mg/mL HPBCD, while the API:HPBCD molar ratio ranges from 1:1 to 1:20. Published labeling for itraconazole IV lists HPBCD at 400 mg/mL and itraconazole at 10 mg/mL, corresponding to a 40:1 weight ratio. The bulk solution is adjusted to pH 4.5–6.5 with citrate, phosphate, or acetate buffer; terminal sterilization at 121 °C for 15 min is used only where thermal stability allows, otherwise aseptic filtration through 0.22 µm PES or PVDF capsules is required. Compliance anchors are USP <1>, USP <85>, USP <788>, USP <790>, EP 2.6.14, EP 2.9.19, and ICH Q3D. Production-scale failure modes include foam formation during nitrogen sparging, filter flux decay as HPBCD concentration rises, and post-sterilization sub-visible particle shifts because the thermal hold can alter drug-cyclodextrin complex equilibrium. Acid-catalysed hydrolysis of HPBCD is pH-dependent and becomes a process risk below pH 4.0. For novel APIs, published forced degradation data in this exact configuration are limited; therefore, pre- and post-sterilization sub-visible particle counts must be generated for each formulation. Terminal product types include IV concentrate, IM injection, and subcutaneous injection. High HPBCD osmolality contributes to renal clearance, and the osmolality contribution from the accumulated carrier must be assessed against route-specific clinical limits.

Impeller Tip Speed and Granule Porosity in HPBCD Wet Granulation

Tablet formulations that incorporate hydroxypropyl betadex through wet granulation use the material as both a solubilizing inclusion agent and a binder solution component. The addition ratio is 2–10% w/w of final tablet mass, with API:HPBCD molar ratios of 1:1 to 1:3; higher ratios are restricted by tablet weight and disintegration time. The binder solution is prepared by dissolving HPBCD in purified water at 20–40% w/w and sprayed onto the dry blend in a high-shear granulator with impeller tip speed 2–5 m/s and chopper speed 1000–3000 rpm. Spray rate is maintained at 50–150 g/min/kg of dry powder, and wet massing continues until a predefined torque value is reached. The wet granulate is milled through a 1.5 mm screen, dried in a fluid-bed dryer at 40–55 °C inlet air to loss on drying 1.0–2.0%, and compressed on a rotary tablet press at 10–25 kN. Compliance anchors are USP <711> for dissolution, USP <905> for uniformity of dosage units, USP <1217> for tablet breaking force, and EP 2.9.8 for resistance to crushing. Terminal product types include immediate-release tablets and orally disintegrating tablets when superdisintegrants are added. The dominant processing boundary is moisture: at relative humidity above 60%, HPBCD adsorbs water, granule porosity falls, and sticking on the tablet press becomes frequent. Compression suites with RH controlled at 35–45% and external lubrication with magnesium stearate at 0.5–1.0% w/w reduce the risk of picking and capping. If impeller tip speed is set too high, localized temperature rise softens the HPBCD binder and produces dense granules with slow disintegration; published data for this specific configuration are limited, so torque, granule-size distribution, and tablet dissolution are monitored batch-to-batch rather than inferred from placebo behavior.

For BCS Class II APIs formulated as powder-filled hard capsules, hydroxypropyl betadex is used as a dry-state stabilizer and dissolution-rate enhancer without requiring pre-formation of an isolated inclusion complex. The addition ratio is 10–50% w/w of capsule fill weight, with API:HPBCD molar ratios of 1:1 to 1:4; higher ratios are reserved for low-dose compounds because size 00 capsules are limited to approximately 700 mg total fill. The downstream production process consists of blending in a V-blender or bin blender at 50–80% fill volume and 10–25 rpm for 10–20 min, followed by encapsulation on a tamping-pin or dosator machine. Compliance for the terminal capsules is established by USP <701> for disintegration and USP <711> for dissolution. Terminal product types are hard gelatin and HPMC capsules. The main operational limit is moisture: HPBCD becomes hygroscopic above 60% RH, which reduces powder flow and may soften capsule shells; desiccant loading and low-moisture-permeability packaging are required to keep fill moisture below 2.0%.

When Lyophilization Chamber Pressure Must Remain Below 200 µbar for High-HPBCD Formulations

Production of lyophilized injectable cakes from HPBCD-rich solutions applies sterile-product controls and adds thermal-cycle control for water removal and cake structure. The pre-lyophilization addition ratio is 2–10% w/v HPBCD; API:HPBCD molar ratios range from 1:1 to 1:20, with the higher end required when the API would otherwise crystallize during freezing. Type I glass vials are loaded on 316L stainless steel shelves; the solution is frozen to -40 °C or lower, annealed near -10 °C for 2–4 h to promote ice crystallization, and primary-dried at a shelf temperature of -25 °C and chamber pressure of 50–200 µbar for 24–72 h. Secondary drying is conducted at 20–30 °C for 6–12 h until Karl Fischer residual moisture is NMT 1.0%. Compliance uses USP <921> for water content, USP <788> and EP 2.9.19 for sub-visible particles, and ICH Q3D for elemental impurities. Terminal product types are sterile powder for injection and reconstituted IV or IM solution. The main collapse risk arises because HPBCD forms an amorphous matrix with a lower collapse temperature than crystalline bulking agents; if product temperature exceeds the collapse temperature during primary drying, the cake undergoes macro-collapse, yielding high residual moisture, poor cake morphology, and extended reconstitution time. Freeze-drying microscopy is required because published collapse temperatures for novel HPBCD-API systems are frequently unavailable; batch-to-batch variance in HPBCD degree of substitution can shift the glass transition and must be trended. Production-scale failure modes include vial breakage after annealing and non-uniform cake height across the shelf when filtration pressure drop reduces fill-volume consistency.

In oral liquid vehicles, the ability of hydroxypropyl betadex to complex hydrophobic APIs creates a preservative efficacy constraint that must be resolved during formulation development. Addition ratios are 20–40% w/v HPBCD in oral solutions, with API:HPBCD molar ratios of 1:1 to 1:5. The production process uses low-shear mixing in stainless steel or glass-lined vessels at 25–40 °C, with pH maintained between 3.0 and 6.0 using citrate or phosphate buffers. Compliance is based on USP <51> for antimicrobial effectiveness, USP <922> for water activity, and ICH Q3D for elemental impurities. Terminal product types include oral solutions, reconstitutable suspensions, and pediatric drops. The known formulation conflict is that HPBCD can complex paraben and benzoate preservatives, reducing the free preservative fraction below the concentration required to pass USP <51>; antimicrobial effectiveness must therefore be tested on the final formulation, not a preservative-free placebo. In production, higher HPBCD concentrations increase solution viscosity and can generate foam during low-shear mixing; vacuum deaeration or nitrogen overlay before filling is used to minimize air entrapment and fill-volume variation.

Fluidized-bed spray granulation of hydroxypropyl betadex-containing oral granules requires control of droplet size to avoid uncontrolled agglomeration and loss of reconstitution rate. HPBCD is incorporated at 5–30% w/w of the granule formulation, either dissolved in the binder solution at 20–40% w/w solids or pre-blended with the API in a high-shear mixer. The downstream process uses a top-spray fluid bed with inlet air temperature 50–70 °C, product temperature 25–35 °C, atomization pressure 1.5–2.5 bar, and spray rate 10–25 g/min/kg. Granules are dried to loss on drying NMT 2.0% and sieved to 850 µm or 500 µm depending on the stick-pack fill specification. Compliance for the terminal granules includes USP <711> for suspension dissolution and USP <905> for single-dose uniformity. Terminal product types are oral granules in stick packs and dry syrups. Overspraying or excessive HPBCD binder concentration produces hard agglomerates that reconstitute slowly; underspraying yields friable granules that segregate during high-speed filling. Because HPBCD is hygroscopic, the final package must use low-moisture-permeability laminated foil with desiccant to maintain granule moisture below 2.0% through shelf life.